ACURX PHARMACEUTICALS INC (ACXP)

US00510M1045 - Common Stock

2.36  +0.03 (+1.29%)

Full profile views are only available for registered users, you can see which data is available below.

Examples of complete profiles are available for MSFT and AAPL.

Registered users have access to more data. Please register or login for additional data.

ACURX PHARMACEUTICALS INC

NASDAQ:ACXP (3/28/2024, 12:02:39 PM)

2.36

+0.03 (+1.29%)

Chartmill TA Rating
Chartmill Setup Rating
Sector
GICS SectorHealth Care
GICS IndustryBiotechnology
Chartmill FA Rating
Valuation
Growth
Profitability
Health
Dividend
Overview
Earnings (Last)
Earnings (Next)
Ins Owners
Inst Owners
Market Cap32.50M
Shares
PEN/A
Fwd PEN/A
Dividend YieldN/A
Analysts
IPO
Stock Screener Links
Screen Image

Nasdaq Stock Screener

Find more stocks on Nasdaq

Screen Image

USA Stock Screener

Find more stocks on the USA

Screen Image

GICS Sector Stock Screener

Find competitors from the same sector on the USA

Screen Image

GICS Industry Stock Screener

Find competitors from the same industry on the USA

Screen Image

Technical Stock Screener

Find stocks with similar TA and Setup ratings on the USA

Screen Image

Fundamental Stock Screener

Find stocks with similar Fundamental rating on the USA

Screen Image

Best Technical Competitors Stock Screener

Find the competitors with the best technical ratings on the USA

Screen Image

Best Technical Setups Competitors Stock Screener

Find the competitors with the best technical and setup ratings on the USA

Screen Image

Best Fundamental Competitors Stock Screener

Find the competitors with the best fundamentals on the USA

Screen Image

Best Valuation Competitors Stock Screener

Find the competitors with the best valuation on the USA

Screen Image

Best Dividend Competitors Stock Screener

Find the competitors with the best dividend on the USA

Screen Image

Best Analyst Rating Competitors Stock Screener

Find the competitors with the best analyst ratings on the USA

ACXP Daily chart

Company Profile

Acurx Pharmaceuticals, Inc. operates as a clinical stage biopharmaceutical company, which engages in developing new antibiotics for infections caused by bacteria listed as priority pathogens. The company is headquartered in Staten Island, New York and currently employs 4 full-time employees. The company went IPO on 2021-06-25. The firm is focused on developing a new class of antibiotics for infections caused by bacteria listed as priority pathogens by the World Health Organization (WHO), the United States Centers for Disease Control and Prevention (CDC) and the United States Food and Drug Administration (FDA). The firm develops antibiotic candidates that block the deoxyribonucleic acid (DNA) polymerase IIIC enzyme (Pol IIIC). Pol IIIC is the primary catalyst for DNA replication in Gram-positive bacterial cells. The Company’s research and development pipeline includes clinical-stage and early-stage antibiotic candidates that target Gram-positive bacteria for oral and/or parenteral treatment of infections caused by Clostridium difficile; Enterococcus, including vancomycin-resistant strain; Staphylococcus, including methicillin-resistant strains, and Streptococcus, including antibiotic resistant strains).

Company Info

ACURX PHARMACEUTICALS INC

259 Liberty Avenue

Staten Island NEW YORK

P: 19175331469

CEO: David P. Luci

Employees: 4

Website: https://www.acurxpharma.com/

ACXP News

News Image9 days ago - ChartmillDiscover the top movers in Tuesday's pre-market session and stay informed about market dynamics.

Tuesday's pre-market session: top gainers and losers

News Image10 days ago - ChartmillCurious about the stocks that are showing activity after the closing bell on Monday?

What's going on in today's after hours session

News Image10 days ago - InvestorPlaceACXP Stock Earnings: Acurx Pharmaceuticals Misses EPS for Q4 2023

ACXP stock results show that Acurx Pharmaceuticals missed analyst estimates for earnings per share the fourth quarter of 2023.

News Image10 days ago - BusinessInsiderACXP Stock Earnings: Acurx Pharmaceuticals Misses EPS for Q4 2023

InvestorPlace - Stock Market News, Stock Advice & Trading Tips Acurx Pharmaceuticals (NASDAQ:ACXP) just reported results for the fourth quarte...

News Image10 days ago - Acurx Pharmaceuticals, Inc.Acurx Pharmaceuticals, Inc. Reports Fourth Quarter and Full Year 2023 Results and Provides Business Update

/PRNewswire/ -- Acurx Pharmaceuticals, Inc. (NASDAQ: ACXP) ("we" or "Acurx" or the "Company"), a clinical stage biopharmaceutical company developing a new...

News Image24 days ago - Acurx Pharmaceuticals, Inc.Acurx Pharmaceuticals, Inc. to Discuss Fourth Quarter and Full Year 2023 Financial Results on March 18, 2024 Conference Call and Provide Business Update

/PRNewswire/ -- Acurx Pharmaceuticals, Inc. (NASDAQ: ACXP) ("Acurx" or the "Company"), a clinical stage biopharmaceutical company developing a new class of...

ACXP Twits

Here you can normally see the latest stock twits on ACXP, but your cookie settings prevent this from loading. You can edit your cookie settings in our cookie consent dialog.

Example Twits:

Twits example